Quick Answer
Alaunos Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2022.
Alaunos Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2022 | $0.00 | -100.0% |
| 2021 | $16.25M | — |
| 2020 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $0.00 | -100.0% | -100.0% |
| June 30, 2022 | $4.47M | — | -56.7% |
| March 31, 2022 | $10.32M | — | -36.5% |
| December 31, 2021 | $16.25M | — | +33.5% |
| September 30, 2021 | $12.17M | — | — |
| December 31, 2020 | $0.00 | — | — |
- Alaunos Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 7, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: